Contribution of trifluoperazine metabolites to the in vivo 19F NMR spectrum of rat brain

Magnetic Resonance in Medicine

Volumn 43, Issue 5, 2000, Pages 756-759

  Lindquist, Diana M ^a   Dachtler, Markus ^b   Hawk, Roger M ^a   Karson, Craig N ^c,d   Albert, Klaus ^b   Komoroski, Richard A ^c,d  

^a Univ of Arkansas at Little Rock ^*  (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Animal model; Metabolism; Neuroleptic; Psychotropic drug; Schizophrenia

Indexed keywords

BIOMOLECULES; CHLORINE COMPOUNDS; HISTOLOGY; METABOLISM; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TISSUE;

ANIMAL MODEL; ANTIPSYCHOTIC DRUG; MULTIPLE RESONANCES; NEUROLEPTIC; NMR SPECTRUM; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; TRIFLUOPERAZINE;

METABOLITES;

FLUOXETINE; NORFLUOXETINE; TISSUE EXTRACT; TRIFLUOPERAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTRAST ENHANCEMENT; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RADIOFREQUENCY; RAT; SCHIZOPHRENIA; SPECTROMETER;

EID: 0034109903     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2594(200005)43:5<756::AID-MRM19>3.0.CO;2-U     Document Type: Article

References (14)

1. 19F-MRS: a new tool for psychopharmacology. In: Nasrallah HA, Pettegrew JW, editors. NMR spectroscopy in psychiatric brain disorders. Washington: American Psychiatric Press; 1995. p 213-234.
2. 19F MR spectroscopy. J Neural Trans [Gen Sect] 1995;99:1-6.
3. 19F NMR studies of drugs in brain. Curr Sci 1999;76:789-793.
4. 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Reson Med 1994;31:204-211.
5. 19F NMR rotating frame zeugmatography. Magn Reson Imaging 1989;7:543-545.
6. 19F-NMR Spektroskopie von Neuroleptika im Gehirn. PhD dissertation, University of Tübingen; 1992.
7. Mahju MA, Maickel RP. Accumulation of phenothiazine tranquilizers in rat brain and plasma after repeated dosage. Biochem Pharmacol 1969;18:2701-2710.
8. Breyer U, Prox A, Bertele R, Gaertner HJ. Tissue metabolites of trifluoperazine, fluphenazine, prochlorperazine, and perphenazine in the rat: identification and synthesis. J Pharm Sci 1974;63:1842-1848.
9. Breyer U, Gaertner HJ, Prox A. Formation of identical metabolites from piperazine- and dimethylamino-substituted phenothiazine drugs in man, rat, and dog. Biochem Pharmacol 1969;18:777-788.
10. Breyer U, Schmalzing G. Metabolism and disposition of trifluoperazine in the rat. Drug Metab Disp 1977;5:97-103.
11. Schmalzing G. Metabolism and disposition of trifluoperazine in the rat. II. Kinetics after oral and intravenous administration in acutely and chronically treated animals. Drug Metab Disp 1977;5:104-115.
12. West NR, Vogel WH. Absorption, distribution and excretion of trifluoperazine in rats. Arch Int Pharmacodyn 1975;215:318-335.
13. 3H]trifluoperazine in bile fistula rats. Xenobiotica 1978;8:45-54.
14. Everett TS. Nuclear magnetic resonance spectroscopy of organofluorine compounds. In: Hudlicky M, Pavlath AE, editors. Chemistry of organic fluorine compounds II. Washington: American Chemical Society; 1995. p 1037-1086.